Shares of Evoke Pharma Inc. (NASDAQ:EVOK) have received an average rating of “Hold” from the nine brokerages that are covering the stock. One equities research analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and three have given a buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $5.60.

A number of equities analysts recently issued reports on the stock. Noble Financial cut shares of Evoke Pharma from a “buy” rating to a “hold” rating in a research report on Tuesday, July 19th. Northland Securities cut shares of Evoke Pharma from an “outperform” rating to a “market perform” rating in a research report on Monday, July 18th. Rodman & Renshaw reiterated a “buy” rating and set a $27.00 price objective on shares of Evoke Pharma in a research report on Monday, July 11th. Brean Capital reiterated a “buy” rating on shares of Evoke Pharma in a research report on Friday, July 8th. Finally, HC Wainwright set a $2.50 price objective on shares of Evoke Pharma and gave the stock a “hold” rating in a research report on Tuesday, August 16th.

A number of institutional investors have recently made changes to their positions in EVOK. Bank of New York Mellon Corp boosted its stake in Evoke Pharma by 2.0% in the second quarter. Bank of New York Mellon Corp now owns 23,679 shares of the specialty pharmaceutical company’s stock valued at $162,000 after buying an additional 464 shares during the period. State Treasurer State of Michigan purchased a new stake in Evoke Pharma during the second quarter valued at $171,000. Finally, Vanguard Group Inc. boosted its stake in Evoke Pharma by 5.0% in the second quarter. Vanguard Group Inc. now owns 62,381 shares of the specialty pharmaceutical company’s stock valued at $427,000 after buying an additional 2,947 shares during the period. Hedge funds and other institutional investors own 8.19% of the company’s stock.

Evoke Pharma (NASDAQ:EVOK) opened at 1.92 on Monday. Evoke Pharma has a 12 month low of $1.52 and a 12 month high of $11.11. The company’s market capitalization is $23.71 million. The stock’s 50 day moving average is $2.02 and its 200-day moving average is $4.20.

Evoke Pharma (NASDAQ:EVOK) last released its quarterly earnings data on Monday, August 15th. The specialty pharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.43) by $0.02. On average, analysts expect that Evoke Pharma will post ($1.19) EPS for the current year.

About Evoke Pharma

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

5 Day Chart for NASDAQ:EVOK

Receive News & Stock Ratings for Evoke Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma Inc. and related stocks with our FREE daily email newsletter.